Mousseaux C, Dupont A, Rafat C, et al. - By performing this study on patients with a total calcemia above 12 mg/dL (3 mmol/L) admitted in two ICUs from January 2007 to February 2017, researchers determined the clinical and biological characteristics, causes, treatments, and outcome related to severe hypercalcemia (HCM) in this case series, given severe HCM represents a common cause for admission in ICU. This study included 131 patients with HCM. In 58 (44.3%), 29 (22.1%), 16 (12.2%), and in 28 (21.3%) patients, a link of HCM with hematologic malignancy, solid tumors, endocrinopathies, and other causes, respectively, was identified. The only treatment significantly related to a reduction of total calcemia below 12 mg/dL (3 mmol/L) at day 5 was the use of bisphosphonates. ICU rates were estimated to be 9.9% and hospital mortality rates were 21.3%. Multivariate analysis revealed Simplified Acute Physiologic Score (SAPS II) and an underlying solid tumor as independent factors that were related to hospital mortality. Overall, high mortality rates, primarily attributed to underlying malignancies, were reported in relation to HCM. Organ failures may develop to complicate the course of HCM, however, mostly, early ICU management can reverse these. The importance of early ICU admission and prompt HCM management was highlighted, particularly in cases with an underlying solid tumor presenting with neurological symptoms.